CONCLUSION
The elucidation of complex mutation profiles through NGS signifies a paradigm shift in oncological research. Unveiling the co-occurrence of BRAF and HRAS mutations in RMS, especially the enigmatic Class III BRAF mutation, holds the potential to redefine therapeutic strategies. Targeting these unique mutations presents a remarkable opportunity for innovative treatment modalities.